Show simple item record

dc.contributor.authorDuenas-Garcia, Omar Felipe
dc.contributor.authorSierra, Tania
dc.contributor.authorNicasio, Erica
dc.contributor.authorLeung, Katherine
dc.contributor.authorHall, Cynthia D.
dc.contributor.authorFlynn, Michael
dc.date2022-08-11T08:10:06.000
dc.date.accessioned2022-08-23T16:55:43Z
dc.date.available2022-08-23T16:55:43Z
dc.date.issued2017-02-23
dc.date.submitted2017-06-13
dc.identifier.citationFemale Pelvic Med Reconstr Surg. 2017 Feb 23. doi: 10.1097/SPV.0000000000000404. <a href="https://doi.org/10.1097/SPV.0000000000000404">Link to article on publisher's site</a>
dc.identifier.issn2151-8378 (Linking)
dc.identifier.doi10.1097/SPV.0000000000000404
dc.identifier.pmid28230566
dc.identifier.urihttp://hdl.handle.net/20.500.14038/42772
dc.description.abstractOBJECTIVE: The aim of this study was to determine the effect of preoperative oral phenazopyridine on short-term voiding dysfunction in patients undergoing a retropubic midurethral sling. METHODS: We conducted a retrospective cohort study in subjects undergoing a retropubic midurethral sling comparing those who received preoperative oral phenazopyridine with those who did not. We included all women who underwent a retropubic midurethral sling without concomitant procedures under general anesthesia at our institution. Slings were placed by either suprapubic or transvaginal approach, per surgeon's preference. Demographics and intraoperative data on preoperative dose of phenazopyridine and medications linked to voiding dysfunction were captured. RESULTS: One hundred seventy-four subjects were identified. Twenty-five subjects failed to meet inclusion and exclusion criteria and were excluded, and 149 subjects comprised the final groups. Eighty-two subjects (55.03%) received phenazopyridine, and 67 (44.97%) did not. Most subjects received a 200-mg dose (97.6%). Except for surgical approach, both groups receiving and not receiving phenazopyridine had similar demographic characteristics. Eighty-eight percent of the subjects who received phenazopyridine passed the voiding trial versus 73.1% (odds ratio, 2.98; 95% confidence interval, 1.23-7.17). After adjusting for medications, estimated blood loss, number of trocar passages, or bladder perforation, the patients receiving phenazopyridine were still more likely to pass the postoperative voiding trials compared with those who did not (odds ratio, 2.97; 95% confidence interval, 1.10-7.98). CONCLUSIONS: Our findings suggest that the preoperative administration of phenazopyridine may improve postoperative voiding function after a retropubic midurethral sling. Additional prospective trials are needed to confirm this finding.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28230566&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1097/SPV.0000000000000404
dc.subjectFemale Urogenital Diseases and Pregnancy Complications
dc.subjectMaternal and Child Health
dc.subjectObstetrics and Gynecology
dc.subjectWomen's Health
dc.titleThe Effect of Preoperative Phenazopyridine on Urinary Retention Following Midurethral Sling
dc.typeJournal Article
dc.source.journaltitleFemale pelvic medicine and reconstructive surgery
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/obgyn_pp/129
dc.identifier.contextkey10292820
html.description.abstract<p>OBJECTIVE: The aim of this study was to determine the effect of preoperative oral phenazopyridine on short-term voiding dysfunction in patients undergoing a retropubic midurethral sling.</p> <p>METHODS: We conducted a retrospective cohort study in subjects undergoing a retropubic midurethral sling comparing those who received preoperative oral phenazopyridine with those who did not. We included all women who underwent a retropubic midurethral sling without concomitant procedures under general anesthesia at our institution. Slings were placed by either suprapubic or transvaginal approach, per surgeon's preference. Demographics and intraoperative data on preoperative dose of phenazopyridine and medications linked to voiding dysfunction were captured.</p> <p>RESULTS: One hundred seventy-four subjects were identified. Twenty-five subjects failed to meet inclusion and exclusion criteria and were excluded, and 149 subjects comprised the final groups. Eighty-two subjects (55.03%) received phenazopyridine, and 67 (44.97%) did not. Most subjects received a 200-mg dose (97.6%). Except for surgical approach, both groups receiving and not receiving phenazopyridine had similar demographic characteristics. Eighty-eight percent of the subjects who received phenazopyridine passed the voiding trial versus 73.1% (odds ratio, 2.98; 95% confidence interval, 1.23-7.17). After adjusting for medications, estimated blood loss, number of trocar passages, or bladder perforation, the patients receiving phenazopyridine were still more likely to pass the postoperative voiding trials compared with those who did not (odds ratio, 2.97; 95% confidence interval, 1.10-7.98).</p> <p>CONCLUSIONS: Our findings suggest that the preoperative administration of phenazopyridine may improve postoperative voiding function after a retropubic midurethral sling. Additional prospective trials are needed to confirm this finding.</p>
dc.identifier.submissionpathobgyn_pp/129
dc.contributor.departmentDepartment of Obstetrics and Gynecology, Female Pelvic Medicine and Reconstructive Surgery


This item appears in the following Collection(s)

Show simple item record